Literature DB >> 11176173

Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood.

P J Souter1, S Thomas, A R Hubbard, S Poole, J Römisch, E Gray.   

Abstract

OBJECTIVE: To investigate the effects of antithrombin on lipopolysaccharide (LPS)-induced tissue factor and interleukin-6 (IL-6) production in three different in vitro cellular systems: whole blood, human umbilical vein endothelial cells, and mononuclear cells. DESIGN AND
SETTING: Laboratory in vitro study of the effects of antithrombin on procoagulant activity and cytokine release by LPS-stimulated endothelial and peripheral blood cells.
SUBJECTS: In vitro whole blood, isolated human umbilical vein endothelial cell, and mononuclear cell cultures.
INTERVENTIONS: Addition of antithrombin to LPS-treated whole blood, human umbilical vein endothelial cells, and mononuclear cells. MEASUREMENT AND MAIN
RESULTS: Citrated whole blood, isolated human umbilical vein endothelial cells, or mononuclear cells were stimulated with LPS for 4-6 hrs in the presence or absence of antithrombin. Tissue factor activity was estimated by a tissue factor-dependent clotting or chromogenic assay and IL-6 was measured by specific ELISA. Antithrombin was found to inhibit tissue factor and IL-6 production in all three systems in a dose-dependent manner (0-40 IU/mL). Flow-through fractions of immunoadsorbed antithrombin concentrate were found to be ineffective. Five different batches of the same antithrombin concentrate were tested and the inhibitory activity was found to be consistent throughout all batches. Up to 40 microM of recombinant hirudin, a specific thrombin inhibitor, did not inhibit the production of tissue factor or IL-6 in either of the three cell systems, suggesting that the observed inhibition by antithrombin was not due solely to its ability to inhibit thrombin.
CONCLUSIONS: Apart from the inhibition of thrombin and other activated clotting factors, antithrombin may also down-regulate the cellular expression of proinflammatory cytokines. Consequently, antithrombin concentrates may have value in the treatment of sepsis-induced disseminated intravascular coagulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11176173     DOI: 10.1097/00003246-200101000-00027

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  25 in total

1.  Antimicrobial effects of helix D-derived peptides of human antithrombin III.

Authors:  Praveen Papareddy; Martina Kalle; Ravi K V Bhongir; Matthias Mörgelin; Martin Malmsten; Artur Schmidtchen
Journal:  J Biol Chem       Date:  2014-09-08       Impact factor: 5.157

2.  Up-regulation interleukin-6 and interleukin-8 by activated protein C in lipopolysaccharide-treated human umbilical vein endothelial cells.

Authors:  Yi Li; Bin Du; Jia-qi Pan; De-chang Chen; Da-wei Liu
Journal:  J Zhejiang Univ Sci B       Date:  2006-11       Impact factor: 3.066

3.  The efficacy of recombinant human activated protein C (rhAPC) vs antithrombin III (at III) vs heparin, in the healing process of partial-thickness burns: a comparative study.

Authors:  O Kritikos; M Tsagarakis; D Tsoutsos; C Kittas; V Gorgoulis; A Papalois; A Giannopoulos; G Kakiopoulos; O Papadopoulos
Journal:  Ann Burns Fire Disasters       Date:  2012-06-30

4.  Human Recombinant Antithrombin (ATryn®) Administration Improves Survival and Prevents Intravascular Coagulation After Intraportal Islet Transplantation in a Piglet Model.

Authors:  Valery Gmyr; Caroline Bonner; Ericka Moerman; Antoine Tournoys; Nathalie Delalleau; Audrey Quenon; Julien Thevenet; Mikael Chetboun; Julie Kerr-Conte; François Pattou; Thomas Hubert; Merce Jourdain
Journal:  Cell Transplant       Date:  2016-10-27       Impact factor: 4.064

5.  Impact of antithrombin III on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: an in vivo analysis.

Authors:  Sasa-Marcel Maksan; Zilfi Ulger; Martha Maria Gebhard; Jan Schmidt
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

Review 6.  Biology and pathogenesis of thrombosis and procoagulant activity in invasive infections caused by group A streptococci and Clostridium perfringens.

Authors:  Amy E Bryant
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 7.  Innate immunity, coagulation and placenta-related adverse pregnancy outcomes.

Authors:  Min Li; S Joseph Huang
Journal:  Thromb Res       Date:  2009-08-14       Impact factor: 3.944

8.  Early coagulation disorders after severe burn injury: impact on mortality.

Authors:  Athina Lavrentieva; Theodore Kontakiotis; Militsa Bitzani; Georgia Papaioannou-Gaki; Angeliki Parlapani; Olimpia Thomareis; Nicolaos Tsotsolis; Maria-Amalia Giala
Journal:  Intensive Care Med       Date:  2008-01-12       Impact factor: 17.440

9.  Antithrombin: An anticoagulant, anti-inflammatory and antibacterial serpin.

Authors:  Alireza R Rezaie; Hemant Giri
Journal:  J Thromb Haemost       Date:  2020-03       Impact factor: 5.824

10.  The anti-inflammatory action of Bothrops jararaca snake antithrombin on acute inflammation induced by carrageenan in mice.

Authors:  Karen de Morais-Zani; Fernanda Peixoto Barbosa Nunes; Jacilene Barbosa da Silva; Márcio José Ferreira; Kathleen Fernandes Grego; Mônica Lopes-Ferreira; Aparecida Sadae Tanaka; Anita Mitico Tanaka-Azevedo
Journal:  Inflamm Res       Date:  2013-05-12       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.